Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
about
Cytomegalovirus infection in immunosuppressed patients after kidney transplantationAntiviral drug resistance of human cytomegalovirus.A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.Management of febrile neutropenia: ESMO Clinical Practice Guidelines.Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Progress in the development of new therapies for herpesvirus infectionsDetailed polymorphism study on cytomegalovirus DNA polymerase gene to reveal the most suitable genomic targets for quantitative Real-time PCREfficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model.A First-in-Human Study To Assess the Safety and Pharmacokinetics of Monoclonal Antibodies against Human Cytomegalovirus in Healthy VolunteersSelection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses.In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection.Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cellsPhase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients.The search for new therapies for human cytomegalovirus infections.Immune response to CMV in solid organ transplant recipients: current concepts and future directions.Current diagnostic and treatment strategies for cardiac allograft vasculopathy.Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.The human cytomegalovirus chemokine receptor homolog encoded by US27.Active CMV and EBV infections in renal transplant recipients with unexplained fever and elevated serum creatinine.Derivatives of mesoxalic acid block translocation of HIV-1 reverse transcriptase.Cytomegalovirus infection and ganciclovir resistance caused by UL97 mutations in pediatric transplant recipients.The human cytomegalovirus terminase complex as an antiviral target: a close-up view.Rapid detection and quantitation of ganciclovir resistance in cytomegalovirus quasispecies.Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.Identification of Amino Acids Essential for Viral Replication in the HCMV Helicase-Primase Complex
P2860
Q26740169-219B3A2F-7D4B-40C3-8E85-0308373B44B6Q30430427-27ABC0A9-00BC-48A6-8DAF-04C4A63C5B17Q33964131-290D1F19-1FF3-475B-BD31-7DE838E445E6Q34620670-F088135F-E88E-4C1F-8D5D-FA53D6784B76Q34678894-4AAC4226-5AA9-4C13-BEA6-929B5CCFC3E9Q35270303-72B35671-580D-46B5-99DB-5D3D9C622B58Q35590695-5F37C288-843A-4518-A94D-2601EE9AAF11Q36124353-810D85D2-F674-4440-8C38-88EDFD429340Q36171970-8E30C337-68B0-4531-B3AB-00B8DEB8668FQ36888046-72298F58-3059-4981-ACAD-8AC3A6B705A4Q36969798-BA7A211E-0676-4284-BDF5-9856EB8417C2Q37036545-8F52EC92-4140-4A1B-86C2-99DB4A80CC30Q37120061-8C6B2037-9613-4286-86F0-4858599C605CQ37173390-1B5AFB23-9A47-40D8-B485-9351AB69B192Q37254190-A554EAA3-5DEC-4F6C-BF45-B9FF8DA81807Q37561897-1971D8EC-9A19-4FA7-AA99-521803F4F973Q37612990-2DACDF37-85F2-449A-A220-2526ABB0A7F7Q37811458-AEA82CAC-0B31-41D6-8083-BFC13BC10B64Q38011227-D0ED8C5C-FA21-4707-91F9-6A25426299DBQ38592122-3AC942E6-1762-415B-9761-056980E6E972Q38796141-CB05766D-E229-475E-B93F-F35B79FD6120Q39074863-356B151B-5A74-40F1-B6F2-1B33B3A1C3B4Q39265988-909BDA77-AC39-4D47-B5B2-D0DA3B1F4357Q40081694-9B866C11-88F7-4D97-A08F-AD4C26459525Q42182643-794AB086-B7D0-46FA-A87E-8CD485607DB6Q43869508-F127552E-95CA-4FD0-8359-99A4BDFE822CQ47549828-B4366B98-275B-4F71-8B8B-9F46C9D10BF3Q48039802-6A2E3606-D043-498E-B8B6-6121445AC794Q53651832-765EFA07-A498-44A1-BB64-268D11B0A093Q58572995-B39E0C0D-6BEE-4B5A-BABD-4FB524F12256
P2860
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@en
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@nl
type
label
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@en
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@nl
prefLabel
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@en
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@nl
P356
P1476
Immunocompromised hosts: persp ...... d-organ transplant recipients.
@en
P2093
Gilberto Torres-Madriz
Helen W Boucher
P304
P356
10.1086/590934
P407
P577
2008-09-01T00:00:00Z